BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...
Nuclear Fuels Inc. (CSE: NF) (OTCQX: NFUNF) ("Nuclear Fuels" or the "Company") announced today it has closed its non-brokered ...
Affinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.
The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting the placement ...
The company plans to use the proceeds to support exploration at the Lunahuasi project in Argentina and the Los Helados ...
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...
Bioscience Corp. (Nasdaq:LEXX; LEXXW), a developer of drug delivery platforms, today announced that it has closed a ...
The Units issued pursuant to the second tranche of the Offering are subject to a four-month hold period under applicable Canadian securities laws that expires February 16, 2025.